The Inflammasome Adaptor Protein ASC in Plasma as a Biomarker of Early Cognitive Changes

Overview of attention for article published in International Journal of Molecular Sciences, July 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 7 news outlets

Readers on

mendeley: 22 Mendeley

So far, Altmetric has seen 7 news stories from 7 outlets.

The Inflammasome Adaptor Protein ASC in Plasma as a Biomarker of Early Cognitive Changes.

Alzforum, 02 Aug 2024

Cyr B, Curiel Cid R, Loewenstein D, Vontell RT, Dietrich WD, Keane RW, de Rivero Vaccari JP.

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

Crwe World, 29 Jul 2024

This data supports the potential of plasma ASC levels as a biomarker for early stages of cognitive decline, based on elevated…

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

Stockwatch, 29 Jul 2024

This data supports the potential of plasma ASC levels as a biomarker for early stages of cognitive decline, based on elevated…

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

ADFN, 29 Jul 2024

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 3 additional news stories.